1,142,768 Shares in Spyre Therapeutics, Inc. (NASDAQ:SYRE) Acquired by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. bought a new position in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 1,142,768 shares of the company’s stock, valued at approximately $33,609,000.

Several other large investors have also added to or reduced their stakes in SYRE. Amalgamated Bank bought a new stake in shares of Spyre Therapeutics during the 2nd quarter valued at $28,000. Quest Partners LLC purchased a new stake in Spyre Therapeutics in the 2nd quarter worth $36,000. SG Americas Securities LLC bought a new stake in Spyre Therapeutics during the second quarter valued at about $130,000. Carlyle Group Inc. purchased a new position in shares of Spyre Therapeutics in the second quarter valued at about $227,000. Finally, Profund Advisors LLC bought a new position in shares of Spyre Therapeutics in the second quarter worth about $296,000. Hedge funds and other institutional investors own 80.39% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on SYRE shares. Evercore ISI started coverage on shares of Spyre Therapeutics in a research report on Tuesday, July 16th. They set an “outperform” rating on the stock. Wedbush began coverage on shares of Spyre Therapeutics in a research note on Wednesday, September 4th. They issued an “outperform” rating and a $45.00 price target on the stock. Ten equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $43.43.

Spyre Therapeutics Stock Up 0.3 %

Shares of NASDAQ:SYRE opened at $33.70 on Friday. The firm has a fifty day simple moving average of $28.91 and a two-hundred day simple moving average of $30.48. Spyre Therapeutics, Inc. has a 52 week low of $8.43 and a 52 week high of $47.97. The stock has a market capitalization of $1.36 billion, a P/E ratio of -0.47 and a beta of 2.92.

Spyre Therapeutics (NASDAQ:SYRE) last released its quarterly earnings results on Wednesday, August 7th. The company reported ($0.86) EPS for the quarter, topping the consensus estimate of ($0.90) by $0.04. On average, analysts expect that Spyre Therapeutics, Inc. will post -3.68 earnings per share for the current year.

Spyre Therapeutics Profile

Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).